Adding ribociclib (Kisqali) to a nonsteroidal aromatase inhibitor (NSAI) produced an overall survival (OS) benefit vs NSAI ...
Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in ...
Posters presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid examined how genomic testing ...
In October 2026, the Vatican announced that Pope Leo XIV had undergone a right lower lobectomy to remove a lung nodule that ...
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can ...
Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, ...
ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in ...
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease ...
Sofetabart mipitecan (Sofe-M), an investigational folate receptor α (FRα)–directed antibody-drug conjugate (ADC), yielded ...
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection. Matthew J. Frigault, MD, and Adam D. Cohen, ...
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal ...
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results